Stockholm – Swedish Medivir AB has released good news on its lead compound TMC435. The protease inhibitor is intended for the therapy of treatment-naïve patients carrying the genotype-1 hepatitis C virus (HCV). In the PILLAR Phase IIb study, 83% of patients treated with TMC435 had reached undetectable levels of HCV-RNA within 24 weeks of receiving the last dose of the protease inhibitor.Jansen Pharmaceutica recently launched a research collaboration with Medivir for the discovery of dengue fever drugs. Medivir CEO Ron Long said that the alliance was “an example of Medivir’s maturing business model,” since both companies will contribute equally to research costs. Up until now, the company has favoured a business model focussed on licensing.